Skip to main content

Table 2 Comparisons between patients with or without anemia

From: Prevalence and management of post-transplant anemia in long-term follow-up of Chinese kidney transplant recipients: a single-center report

  1 year post-transplant 5 years post-transplant
Anemic Non-anemic P value Anemic Non-anemic P value
  (n = 15) (n = 125) (n = 23) (n = 95)
Age (years) 38 ± 11.8 38.9 ± 10.3 0.744 40.3 ± 9.1 42.3 ± 10.2 0.385
Gender (male/female) 10/5 88/37 0.766 16/7 69/26 0.769
BUN (mmol/L) 10.8 ± 6.1 6.9 ± 2.0 0.001 13.5 ± 8.1 7.1 ± 2.2 <0.001
Creatinine (mg/dL) 1.8 ± 0.6 1.3 ± 0.3 0.001 2.0 ± 0.8 1.3 ± 0.2 <0.001
Ccr
Mean 51.1 ± 20.8 69.1 ± 17.3 <0.001 48.1 ± 21.9 65.8 ± 13.7 <0.001
>75 mL/min/1.73 m2 2 (13.3%) 40 (32%) 0.136 4 (17.4%) 25 (26.3%) 0.372
50 to 75 mL/min/1.73 m2 4 (26.7%) 70 (56%) 0.032 4 (17.4%) 61 (64.2%) <0.001
<50 mL/min/1.73 m2 9 (60%) 15 (12%) <0.001 15 (65.2%) 9 (9.5%) <0.001
Immunosuppression
Tac/CsA 3/12 30/95 0.73 3/20 28/67 0.108
MMF/AZT 12/3 110/15 0.382 21/2 81/14 0.448
ACEI or ARB (yes/no) 1/14 19/106 0.372 5/18 16/79 0.58
Iron medicine (yes/no) 11/4 12/113 <0.001 17/6 6/89 <0.001
  1. ARB, angiotensin receptor blockers; ACEI, angiotensin-converting-enzyme inhibitors; AZT, azathioprine; BUN, blood urea nitrogen; Ccr, calculated creatinine clearance; CsA, cyclosporin A; MMF, mycophenolate mofetil; Tac, tacrolimus.